肝炎研究组

(一)本组简介

本研究小组主要负责人为袁权副教授,现有教师2名,依托厦门大学分子疫苗学和分子诊断学国家重点实验室、国家传染病诊断试剂与疫苗工程技术研究中心开展研究工作。本研究小组重点发展乙型病毒性肝炎创新诊疗技术和药物,围绕这一目标开展分子病毒学、免疫学、临床检验诊断学、流行病学和转化医学研究,具体主要包括:

(1)针对持续性病毒感染的治疗性抗体与治疗性疫苗研究;

(2)慢性乙型肝炎治疗应答和转归指导预测诊断新靶标研究;

(3)模拟人类HBV感染致病的细胞与动物模型研究;

(4)HBV感染及其相关疾病的血清与分子流行病学研究;

(5)持续性病毒感染与肿瘤的免疫逃逸机制及治疗新技术。

本研究小组近年来累计发表SCI研究论文60余篇;已有4项发明专利获得国内外11件授权,研究成果转化的诊断产品累计9项获得CFDA注册证书,1项欧盟CE认证,多次获得福建省及厦门市科技进步奖等荣誉。

(二)指导教师

袁权,博士,副教授,博士生导师。Email: yuanquan@xmu.edu.cn

张天英,博士,助理教授。Email: tyzhang1003@163.com

(三)近年来本小组成员作为第一或通讯作者(含共同)发表的部分代表性论文:

1. Zhang TY†, Chen HY†, Cao JL†, Xiong HL, Li TL, Kang XZ, Zhao JH, Yin B, Yuan Q*, Xue D*, Xia NS*. Yuan YA. Structural and functional analyses of the Hepatitis B virus X protein BH3-like domain and its interaction with Bcl-xL. Nature Communications. 2019, June. Accepted. (IF: 11.878)

2. Zhang TY†, Guo XR†, Wu YT†, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Chen PJ, Zhang J*, Yuan Q* and Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2019. DOI:10.1136/gutjnl -2018-317725 (IF: 17.943)

3.Yuan L†, Zhang Y†, Liu X†, Chen Y, Zhang L, Cao J, Li X, Wang M, Wu K, Zhang J, Liu G, Tang Q, Yuan Q*, Cheng T*, Xia N*. Agonist c-Met Monoclonal Antibody Augments the Proliferation of hiPSC-derived Hepatocyte-Like Cells and Improves Cell Transplantation Therapy for Liver Failure in Mice. Theranostics. 2019; 9(7):2115-2128. (IF: 8.063)

4. Zhang YL†, Gao Y†, Cao JL, Zhao JH, Zhang TY, Yang CL, Xiong HL, Wang YB, Ou SH*, Cheng T, Chen CR*, Yuan Q*, Xia NS. Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus. Emerg Microbes Infect. 2019;8(1):724-733. (IF: 6.212)

5. Liu X†, Yuan L†, Zhang L, Mu Y, Li X, Liu C, Lv P, Zhang Y, Cheng T, Yuan Q*, Xia N, Chen X, Liu G*. Bioinspired Artificial Nanodecoys for Hepatitis B Virus. Angewandte chemie-international edition. 2018; 57(38):12499-12503. (IF: 12.102)

6. Zhang JF†, Xiong HL†, Cao JL, Wang SJ, Guo XR, Lin BY, Zhang Y, Zhao JH, Wang YB, Zhang TY*, Yuan Q*, Zhang J, Xia NS. A cell-penetrating whole molecule antibody targeting intracellular HBx suppress hepatitis B virus via TRIM21-dependent pathway, Theranostics.2018, 8(2): 549-562. (IF: 8.063)

7. Yuan L†, Liu X†, Zhang L, Zhang Y, Chen Y, Li X, Wu K, Cao J, Hou W, Que Y, Zhang J, Zhu H, Yuan Q, Tang Q, Cheng T, Xia N. Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection. Emerg Microbes Infect. 2018;7(1):144. (IF: 6.212)

8. Zhang TY†, Yuan Q†,*, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, Cao JL, Guo XR, Liu X, Mo XB, Luo WX, Cheng T, Chen YX, Tao MH, Shih JW, Zhao QJ, Zhang J, Chen PJ, Yuan YA*, Xia NS*, Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut, 2016, 65(4): 658-71. (IF: 17.943)

9. Fan F†, He Z†, Kong LL†, Chen Q†, Yuan Q†, Zhang S, Ye J, Liu H, Sun X, Geng J, Yuan L, Hong L, Xiao C, Zhang W, Sun X, Li Y, Wang P, Huang L, Wu X, Ji Z, Wu Q, Xia NS, Gray NS, Chen L, Yun CH*, Deng X*, Zhou D*. Pharmacological targeting of kinases mst1 and mst2 augments tissue repair and regeneration. Science Translational Medicine, 2016; 8(352), 352ra108. (IF: 17.161)

10. Fan R†, Sun J†, Yuan Q†, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N*, Hou J*. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016, 65(2):313-20. (IF: 17.943)

11. Hou FQ†, Song LW†, Yuan Q, Fang LL, Ge SX, Zhang J, Sheng JF, Xie DY, Shang J, Wu SH, Sun YT, Wei SF, Wang MR, Wan MB, Jia JD, Luo GH, Tang H, Li SC, Niu JQ, Zhou WD, Sun L*, Xia NS*, Wang GQ*. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics. 2015; 5(3):218-26. (IF: 8.063)

12. Song LW†, Wang YB†, Fang LL, Wu Y, Yang L, Chen JY, Ge SX, Zhang J, Xiong YZ, Deng XM, Min XP*, Zhang J, Chen PJ, Yuan Q*, Xia NS. Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping. Anal Chem. 2015;87(10):5173-80. (IF: 6.350)

13. Song LW†, Liu PG†, Liu CJ, Zhang TY, Cheng XD, Wu HL, Yang HC, Hao XK, Yuan Q*, Zhang J, Kao JH, Chen DS, Chen PJ*, Xia NS*. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect. 2015; 21(2):197-203. (IF: 6.452)

14. Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, Yan Y, Ge SX, Wang YB, Peng CY, Zhang J*, Kao JH, Chen DS, Chen PJ*, Xia NS*. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut. 2013; 62(1):182-4. (IF: 17.943)

15. Geng X†, Huang C†, Qin Y, McCombs JE, Yuan Q, Harry BL, Palmer AE, Xia NS*, Xue D*. Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction. Proc Natl Acad Sci U S A. 2012;109(45):18471-6. (IF: 9.580)

16. Huang CH†, Yuan Q†, Chen PJ, Zhang YL, Chen CR, Zheng QB, Yeh SH, Yu H, Xue Y, Chen YX, Liu PG, Ge SX, Zhang J*, Xia NS*. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012; 57(4):720-9. (IF: 18.946).

(四)研究成果转化的已上市产品

1. 乙型肝炎病毒基因分型检测试剂盒(荧光免疫层析法)。国械注准20193400032。

2. 乙型肝炎病毒核心抗体测定试剂盒(双抗原夹心化学发光微粒子免疫检测法)。国械注准20173401378。

3. 乙型肝炎病毒核酸相关抗原检测试剂盒。国食药监械(准)字2010第3400614号。

4.乙型肝炎病毒核心抗体双抗原夹心法检测试剂盒。国食药监械(准)字2010第3401232号。

5. 乙型肝炎病毒表面抗原检测试剂盒(HBsAg Ultra)。国食药监械(准)字2011第3400140号, CE Marketed, No. 41055/101/1/2012/CE。

6. 甲型H1N1流感病毒(2009)HA抗原检测试剂盒。国食药监械(准)字2010第3400974号。

7. 甲型流感病毒抗原检测试剂盒.国食药监械(准)字2009第3400979号。

8. 丁型肝炎病毒IgG抗体检测试剂.国食药监械(准)字2012第3400893号。

9. 丁型肝炎病毒IgM抗体检测试剂.国食药监械(准)字2012第3400895号。

(五)本组优势

研究兴趣广泛,技术平台多样化,与国内外高校、科研院所及生物医药企业合作紧密,学生有较多机会学习到生物医药领域从基础研究到应用转化过程的各个环节中的知识和技术,培养全方位能力。研究小组2009年成立至今,已经毕业博士及硕士研究生近30余人,学生毕业后主要从事科学研究(国内外高校及研究所)、医药及诊断企业、生物医药投研等相关工作。

(六)招生条件

主要对口本科专业:生物学(含生物信息学)、公共卫生与预防医学、临床检验诊断学、药学等,其他专业可邮件咨询。


上一条:POCT研究组

国家传染病诊断试剂与疫苗工程技术研究中心(厦门大学)  地址:中国福建省厦门市翔安区翔安南路厦门大学翔安校区
电话:0592-2183111 传真:0592-2181258  邮编:361102
ICP备案号:D200327